Alicia Morgans, MD

Alicia Morgans, MD, MPH Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts. She is a clinician and physician investigator specializing in investigating complications of systemic therapy for prostate cancer survivors. She has expertise in clinical trials and patient-reported outcome measures, and as well as incorporating patient preferences and beliefs into clinical decision making.

Dr. Charles J. Ryan, MD

Charles J. Ryan, MD is the B.J. Kennedy Chair in Clinical Medical Oncology at the University of Minnesota and Director of the Division of Hematology, Oncology and Transplantation. He previously held the position of Professor of Clinical Medicine and Urology and the Clinical Program Leader for Genitourinary Medical Oncology at the UCSF Helen Diller Family Comprehensive Cancer Center

Clinician voices sharing insights View all
Physician-Scientist Review Articles
State of the Evidence Review Articles
Written by Christopher J.D. Wallis, MD, PhD, and Zachary Klaassen, MD MSc
April 21, 2021
In 2021, there will be an estimated 9,470 new cases of testicular cancer in the United States with an estimated 440 testis cancer-related deaths.1 Importantly, the vast majority of men with testis cancer, even in advanced stages, are cured as a result of the success of high dose chemotherapy regimens that are tolerated by this typically young and healthy patient population. Given both the relatively young age at diagnosis and overall high survival rates, there has been a much needed and welcome focus on survivorship for testicular cancer patients.

Conference Coverage
Conference Highlights Written by Physician-Scientist
Presented by Quoc-Dien Trinh, MD
In the Society of Urologic Oncology (SUO) plenary session held at the American Urological Association (AUA) Virtual Annual Meeting this afternoon, Dr. Quoc-Dien Trinh addressed the question of how the COVID-19 pandemic has affected the diagnosis of urologic cancers.
Presented by André Deschamps, MD
( André Deschamps, MD, presented a study assessing the quality of life of patients after being treated for prostate cancer. The study involved a 20-minute online survey intended for patients with prostate cancer who received treatment in Europe. It is an observational one-arm study, aiming to examine the quality of life of prostate cancer patients in Europe.
Presented by Elizabeth Wulff-Burchfield, MD
( Elizabeth Wulff-Burchfield, MD, is a medical oncologist specializing in palliative care. At the 2020 Society of Urologic Oncology Virtual Webcast, she discussed supportive and palliative care for urologists.
Presented by Kathryn Hacker Gessner, MD, Ph.D.
Washington, DC ( There is an increasing recognition that postoperative opioid prescriptions are contributing to the opioid crisis in the United States. This is in part due to the diversion of excess opioid medications,
Presented by Neeraj Agarwal, MD
Barcelona, Spain ( Androgen deprivation therapy (ADT) has long been considered the standard of care for patients with metastatic prostate cancer, however recent studies have shown improved survival outcomes by adding additional agents.
Presented by Henrik Gronberg, MD, PhD
Barcelona, Spain ( At the prostate cancer poster discussion at ESMO 2019, Dr. Henrik Gronberg provided a discussion of three important abstracts: the updated STAMPEDE “M1|RT Comparison”, as well as patient reported outcomes from both ENZAMET and TITAN.
Presented by Sumanta K. Pal, MD
Chicago, IL ( The landscape of systemic therapy for metastatic renal cell carcinoma (mRCC) is rapidly changing. Beyond the addition of immune checkpoint inhibitor combinations (nivo/ipi), additional TKI’s (cabozantinib),